Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)

Krilogy Financial LLC bought a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 20,800 shares of the biotechnology company's stock, valued at approximately $287,000.

Several other institutional investors have also recently bought and sold shares of the company. State Street Corp lifted its holdings in shares of Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after buying an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Capricor Therapeutics during the third quarter worth $3,806,000. PFM Health Sciences LP acquired a new position in Capricor Therapeutics during the 3rd quarter valued at $2,324,000. Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 84,350 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter worth $426,000. Institutional investors own 21.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CAPR. HC Wainwright reiterated a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an "overweight" rating and a $35.00 price target on the stock. Cantor Fitzgerald increased their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday, November 14th. Maxim Group lifted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Finally, Oppenheimer reissued an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Trading Up 1.5 %

CAPR stock traded up $0.20 during trading on Monday, hitting $13.70. 688,914 shares of the stock traded hands, compared to its average volume of 1,075,567. The stock has a market cap of $622.94 million, a price-to-earnings ratio of -12.92 and a beta of 4.08. Capricor Therapeutics Inc has a one year low of $3.52 and a one year high of $23.40. The company has a 50 day simple moving average of $15.46 and a 200 day simple moving average of $11.60.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.